share_log

10-Q: Q1 2024 Earnings Report

10-Q: Q1 2024 Earnings Report

10-Q：2024财年一季报
美股SEC公告 ·  2024/05/15 07:35

Moomoo AI 已提取核心信息

ZyVersa Therapeutics, a clinical stage biopharmaceutical company, reported its financial results for the quarter ended March 31, 2024. The company experienced a net loss of $2.8 million, a decrease from the $3.5 million net loss in the same period the previous year. Research and development expenses decreased by 51.4% to $513,000, primarily due to lower manufacturing costs for IC100 and reduced payroll costs. General and administrative expenses also saw a reduction of 34.6% to $2.3 million, attributed to decreased payments related to the PIPE shares, lower bonus accruals, and reduced accounting fees. The company's cash position at the end of the quarter was $2.0 million. ZyVersa is focused on developing drugs for renal or inflammatory diseases and has not yet generated revenue from product sales. The company's future plans include continuing the clinical development of its lead drug candidates, VAR 200 and IC 100, and seeking additional funding to support ongoing operations.
ZyVersa Therapeutics, a clinical stage biopharmaceutical company, reported its financial results for the quarter ended March 31, 2024. The company experienced a net loss of $2.8 million, a decrease from the $3.5 million net loss in the same period the previous year. Research and development expenses decreased by 51.4% to $513,000, primarily due to lower manufacturing costs for IC100 and reduced payroll costs. General and administrative expenses also saw a reduction of 34.6% to $2.3 million, attributed to decreased payments related to the PIPE shares, lower bonus accruals, and reduced accounting fees. The company's cash position at the end of the quarter was $2.0 million. ZyVersa is focused on developing drugs for renal or inflammatory diseases and has not yet generated revenue from product sales. The company's future plans include continuing the clinical development of its lead drug candidates, VAR 200 and IC 100, and seeking additional funding to support ongoing operations.
丝维萨治疗公司是一家处于临床阶段的生物制药公司，报告了2024年3月31日结束的季度的财务业绩。公司净亏损280万美元，与去年同期的350万美元净亏损相比有所下降。研发费用下降了51.4%至513,000美元，主要由于IC100制造成本降低以及减少人员薪资支出。总务及管理费用也下降了34.6%至230万美元，这归因于与PIPE股份相关的支付额度降低，奖金计提也降低，以及减少会计费用。该公司季度末的现金头寸为200万美元。丝维萨专注于开发肾脏或炎症性疾病药物，尚未从产品销售中获得营业收入。公司的未来计划包括继续开发其领先的候选药物VAR 200和IC 100，以及寻求进一步的资金支持持续运营。
丝维萨治疗公司是一家处于临床阶段的生物制药公司，报告了2024年3月31日结束的季度的财务业绩。公司净亏损280万美元，与去年同期的350万美元净亏损相比有所下降。研发费用下降了51.4%至513,000美元，主要由于IC100制造成本降低以及减少人员薪资支出。总务及管理费用也下降了34.6%至230万美元，这归因于与PIPE股份相关的支付额度降低，奖金计提也降低，以及减少会计费用。该公司季度末的现金头寸为200万美元。丝维萨专注于开发肾脏或炎症性疾病药物，尚未从产品销售中获得营业收入。公司的未来计划包括继续开发其领先的候选药物VAR 200和IC 100，以及寻求进一步的资金支持持续运营。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

独立文件3  查看翻译

独立文件4  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    相关股票 相关股票
    代码 迷你走势 最新价
    Nutriband
    NTRB
    -- 7.340
    Eterna Therapeutics
    ERNA
    -- 0.635
    Tonix Pharmaceuticals
    TNXP
    -- 0.3190
    ImmunoPrecise Antibodies
    IPA
    -- 0.645
    Sonnet BioTherapeutic
    SONN
    -- 2.0000
    解锁完整榜单
    热门中概股
    追踪最热门的中概股实时资讯。
    热门讨论
    中美谈话新契机，通胀不再？
    🎙️讨论： 1. 你认为特朗普上台后，对华政策将如何影响中国资产？ 2. 美股市场通胀风险下降，有哪些利好板块？ 展开
    中国将在未来一年采取"适度宽松"的货币政策，这是自2011年以来的首次转向宽松。